Stocktoria
Cartesian Therapeutics, Inc. RNAC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-06-22
Cartesian Therapeutics, Inc. statistics & valuation
Market cap$276.8M
P / S99.0×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -5127.1% | -112.8% | -332.3% | 13.1% | -5.4% |
| Net margin | -4658.6% | -199.0% | -844.9% | 31.9% | -30.2% |
| FCF margin | -2838.6% | -84.2% | -197.5% | -29.6% | -72.2% |
| Return on assets | -44.0% | -17.8% | -72.0% | 21.3% | -16.1% |
| Return on equity | 103.2% | 1138.3% | 49.9% | 37.7% | -114.1% |
| Current ratio | 8.65 | 9.43 | 1.33 | 5.91 | 2.00 |
| Revenue growth | -92.8% | 49.6% | -76.5% | 30.2% | 412.6% |
Source: SEC EDGAR filings · CIK 0001453687 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.